Cancer immunity webinar april 29

39
04.29.2015 Maria Shkrob, PhD Sr. Bioinformatics Scientist R&D Solutions, Elsevier [email protected] Cell-Centered Database for Immunology and Cancer Research

Transcript of Cancer immunity webinar april 29

Page 1: Cancer immunity webinar april 29

04.29.2015

Maria Shkrob, PhDSr. Bioinformatics Scientist

R&D Solutions, Elsevier

[email protected]

Cell-Centered Database for Immunology and Cancer Research

Page 2: Cancer immunity webinar april 29

| 2

Page 3: Cancer immunity webinar april 29

| 3

Information avalanche

0

500

1000

1500

2000

2500

3000

3500

2015200519951985197519651955

“Cancer Immunotherapy” in PubMed as of February 12, 2015

Page 4: Cancer immunity webinar april 29

| 4

Below the tip of the iceberg

Image source: Tumor-altered dendritic cell function: implications for antitumor immunity.

Hargadon KM. Front Immunol. 2013 Jul 11;4:192.

Drug Targets

Biomarkers

Cancer

immunotherapy

Page 5: Cancer immunity webinar april 29

Too much information: how

to survive

Our approach

What Pathway Studio has

to offer

Too much information

about cells in particular

Examples of problems that

the database helps to

solve

Today:

Page 6: Cancer immunity webinar april 29

| 6

If only we knew what we know…

Amorphous information Structured information

Image Source: http://www.thesocialleader.com/wp-content/uploads/2011/03/paper-piles.jpg

Text mining: analyzing text to extract information that is useful for particular purposes

Text

mining

• Hard to deal with

• Hard to deal with algorithmically

• Not scalable

• Search

• Visualize

• Network analysis

• Scalable

• Compressed

20km

Page 7: Cancer immunity webinar april 29

| 7

From text to fact

Tregs contribute to the progression of HNSCC

Regulatory

T cell

Head and neck

squamous cell

carcinoma

text

fact

positive

regulation

sentence

5.6 M facts

24 M abstracts

3.5 M full texts

standard name

standard link

standard name

Page 8: Cancer immunity webinar april 29

| 8

Find cells involved in HNSCC

Pathway Studio: manipulate facts not text

96 publications

• type of connection

• sign

• intersect, combine and expand

Visualize

Summarize

Page 9: Cancer immunity webinar april 29

| 9

Pathway Studio Overview

Pathway Studio

ToolsKnowledgebase

Manually

curated

pathways

Ontologies

Biological

relations

extracted from

literature

Experiment analysis:Gene expression

Proteomics

Metabolomics

NGS (beta)

Search

Summarization

Navigation

Visualization

24M abstracts

3.5M full texts

4.8M relations

+836K new

relations

Page 10: Cancer immunity webinar april 29

| 10

Pathway Studio databases

standard name

standard link

standard name

Mammalprotein-centered

ChemEffectdrug-centered

DiseaseFXbiomarker-centered

+Biomarker

facts+Drugs

Proteins +

• diseases

• clinical parameters

• small molecules

• cell processes

• treatments

• genetic change

• state change

• quantitative change

Cells

+Cell facts

Cells

Page 11: Cancer immunity webinar april 29

Finding cells and

facts about cells

Page 12: Cancer immunity webinar april 29

| 12

Have you seen this cell?

full name

nickname

aka

formerly known as

scars

and

marks

for short

Page 13: Cancer immunity webinar april 29

| 13

Epitope

From inconsistent names to standard names

Basic cell“Attribute”

CD4+ CD25 regulatory T cell

T-lymphocyte leukocyte

T-cell leucocytehemopoetic

hemopoietic

haemopoetic

haemopoietic

hematopoetic

hematopoietic

haematopoetic

haematopoietic

regulatory

immunoregulatoryCD4+CD25+

CD25+FOXP3+

CD4+ CD25+ FOXP3+

Page 14: Cancer immunity webinar april 29

| 14

From inconsistent names to standard names

Epitopes

“Attribute”

Basic cell

Standard

cell name

Image source: http://www.biooncology.com/images/therapeutic-targets/b-cell.png

Combination Frequency Standard name

Ep1+ Ep2- BC3 1000 BC4

Ep5+ BC6 2 BC6

Combination Frequency Standard name

Ep1+ Ep2- BC3 1000 BC4

Ep5+ BC6 100 EP5+ BC6

Page 15: Cancer immunity webinar april 29

| 15

Adding cell processes to the mixture

proliferation of

death of

migration of human polarization

cytotoxicity

quantity

It allows to • Have more cell processes in the database

• Assign cell processes to rare cells

• Quickly introduce changes if needed

Standard

cell

name

Page 16: Cancer immunity webinar april 29

| 16

Recognizing cell processes in text

• Information about more specific cell types

• Doubles the number of cell processes compared to Gene Ontology + EmTree

Page 17: Cancer immunity webinar april 29

| 17

Cell-centered database

standard name

standard link

standard name

BETA

Proteins

Clinical

ParametersDiseases

Small

molecules

Cells

Page 18: Cancer immunity webinar april 29

| 18

• What cells are involved in the

disease of interest, and how?

• What proteins/small

molecules affect those cells,

and how?

• What proteins are exposed

on the surface of the cell?

• What proteins are secreted

from the cell?

What questions do we want to be answered?

Page 19: Cancer immunity webinar april 29

| 19

- Protein/gene

- receptor

- ligand

- kinase

- phosphatase

- Complex

- Functional class

- miRNA

protein regulates cell

cell expresses protein:

• surface

• secretion

Cells and proteins

Page 20: Cancer immunity webinar april 29

| 20

• chemicals naturally occurring

in human body

• pharmaceuticals

• biologically active peptides

• antibody drugs

• environmental chemicals,

• products of metabolism

Small molecules affect

cells

Cell produces small

molecule

Cells and small molecules

Page 21: Cancer immunity webinar april 29

| 21

State is changedCells are related to

disease

Quantity is changed

Cells play active role in diseases

Cells and diseases

Page 22: Cancer immunity webinar april 29

| 22

• General disease

properties

• Measurable

parameters

• Scores

Cells and clinical parameters

Cells affect clinical parameters

Page 23: Cancer immunity webinar april 29

| 23

(beta)

Database statistics

Objects

Cells 617

Cell Processes 7 K

Diseases 7.3 K

Clinical Parameters 1.5 K

Proteins and

protein classes

17.7 K

Small molecules 13.5 K

Relations

Regulation 540 K

Cell expression 250 K

Quantitative Change 10 K

State change 7.7 K

Functional Association 31.5 K

Over 830 K new relations

On top of 4.8 million previously extracted relations

Page 24: Cancer immunity webinar april 29

Example 1:

Browse the literature

Page 25: Cancer immunity webinar april 29

| 25

How proteins secreted from breast carcinoma

affect cells involved in its mechanism?

Step 1

What proteins are secreted from

breast carcinoma cells?

Page 26: Cancer immunity webinar april 29

| 26

How proteins secreted from breast carcinoma

affect cells involved in its mechanism?

Step 1

What proteins are secreted from

breast carcinoma cells?

Disease Secretion Protein

Page 27: Cancer immunity webinar april 29

| 27

Disease Secretion Protein

Step 2

What cells are involved

in breast carcinoma?

Cell Regulation Disease

How proteins secreted from breast carcinoma

affect cells involved in its mechanism?

Step 1

Page 28: Cancer immunity webinar april 29

| 28

Step 3

Find proteins that stimulate

pro-disease cells and inhibit

anti-disease cells

Protein Regulation Cell

How proteins secreted from breast carcinoma

affect cells involved in its mechanism?

Step 2

Step 1

Disease Secretion Protein

Cell Regulation Disease

Page 29: Cancer immunity webinar april 29

| 29

How proteins secreted from breast carcinoma

affect cells involved in its mechanism?

Page 30: Cancer immunity webinar april 29

Example 2

Analyze experiments:• Gene expression

• Metabolomics

• Proteomics

• NGS

Page 31: Cancer immunity webinar april 29

| 31

High grade astrocytoma survival

Background: 3-5% of glioblastoma patients survive longer than 3 years

What are the predictors of long survival?

High grade astrocytoma patient survival: brain tumor (GSE33331)

Comparison of surgical brain tumors of the long survival vs average survival

Increased Immune Gene Expression and Immune Cell Infiltration in High Grade Astrocytoma Distinguish Long from

Short-Term Survivors

Donson AM, Birks DK, Schittone SA, Kleinschmidt-DeMasters BK, Sun DY, Hemenway MF, Handler MH, Waziri AE, Wang M, Foreman NK.

J Immunol. 2012 Aug 15; 189(4): 1920–1927.

Page 32: Cancer immunity webinar april 29

| 32

What is needed for long survival?

Survival

over 70

months

vs Functionally

annotate

genes

What processes

are they

involved in?

What pathways

are they

involved in?

Standard

survival

Results depend

on the quality

and granularity

of the database

Page 33: Cancer immunity webinar april 29

| 33

Experiment analysis in Pathway Studio

Page 34: Cancer immunity webinar april 29

| 34

Analysis of genes positively correlating with prognosis

Genes positively

correlated with

survival

Gene Set

Enrichment

Analysis using

Gene Ontology

Immune system

is involved, but

can we be more

specific?

Page 35: Cancer immunity webinar april 29

| 35

Dig deeper into immune component

Gene Ontology

Mammal

ChemEffect

DIseaseFX

Mammal

ChemEffect

DIseaseFX+cells

28 55 63

T cells

B cells

Leukocytes

Lymphocytes

Neutrofils

+

Macrophages

Dendritic cells

Monocytes

T helpers

+

Th1 cells

Th2 cells

Th17 cells

Tregs

CD8+ T cells

immune

processes

in top 100

immune

cells

in top 100

Page 36: Cancer immunity webinar april 29

| 36

Additional cell processes – additional results

Page 37: Cancer immunity webinar april 29

| 37

Does this new information make sense?

Known connections

between immune cells

identified in analysis

and brain tumors

Page 38: Cancer immunity webinar april 29

| 38

• New database is focused on cell-centered

facts

• It adds over 800K new relations and 4.4K

entities to the knowledgebase

• New data can be used to answer complex

biological questions and analyze

experiments

• Flexible recognition of cells and cell

processes allows customization

Summary

Page 39: Cancer immunity webinar april 29

Thank you